Fierce Pharma October 2, 2024
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of powerhouse rival Johnson & Johnson largely thanks to its diabetes and weight loss franchise—the Indianapolis company has poured much of its revenue into new investment.
Wednesday, Lilly took another giant step in that endeavor, revealing that it will build a $4.5 billion R&D and manufacturing facility. Dubbed the Lilly Medicine Foundry, it will “drive innovation in drug production and make medicines for clinical trials,” the company said.
The foundry will add to the massive project Lilly is constructing 30 miles northeast of its headquarters in Lebanon, Indiana, at the LEAP Research and Innovation District. Lilly already has committed...
Today's Sponsors
Today's Sponsor